Lymphoma

淋巴瘤和霍奇金病项目的目标是更好地了解 淋巴样肿瘤的生物学基础，并应用这一知识来提高诊断和治疗水平 这些疾病的治疗。为了实现这一目标，我们有一个广泛的研究计划， 淋巴瘤的发病机制、临床病理关系、新的治疗方法和 临床试验。我们的资源包括10,000例淋巴瘤和5,000例霍奇金淋巴瘤的大型临床数据库 40年随访的淋巴瘤和包含5500个新鲜冷冻的组织库 标本。我们计划中的27名成员代表了学院内的11个部门 医学院和工程学院。淋巴瘤和霍奇金病项目的研究人员 有16项奖学金，包括1个P01奖、1个SCOR奖、1个P20奖、4个R01奖、1个T32奖、3个K奖和其他同行评审奖。这个 2008年，NCI的年度直接支持总额为350万美元。我们的节目强调翻译 从临床到诊断学和新疗法的研究以及从临床到实验室的研究 与临床事件相匹配的组织研究的相关性。在过去的五年里，超过300人 出版物已经出现在同行评议的期刊上。以实验室为基础的项目侧重于 检测单个细胞中的信号通路；淋巴肿大，注意MYC 癌基因与丙型肝炎的免疫应答；新的诊断方法的发展，包括新的 针对这些基因的基因发现和新的单抗；以及 治疗性疫苗接种的新方法。我们的临床研究重点是免疫疗法和新的 我们小组的综合治疗和概念已经进入了有影响力的第三阶段 东方合作肿瘤学小组(ECOG)的临床试验。

The goal of the Lymphoma and Hodgkin Disease Program is to gain a better understanding of the biology underlying lymphoid neoplasms and to apply this knowledge to improve the diagnosis and treatment of these disorders. In working toward this goal, we have a broad research program with major themes of lymphoma pathogenesis, clinical pathological relationships, novel therapeutics and clinical trials. Our resources include a large clinical database of >10,000 lymphoma and 5,000 Hodgkin lymphoma over a follow-up period of 40 years and a tissue bank containing 5,500 fresh-frozen specimens. The 27 members within our program represent 11 departments within the School of Medicine and the School of Engineering. Investigators in the Lymphoma and Hodgkin Disease Program have 16 grants, including 1 P01; 1 SCOR; 1 P20; 4 R01; 1 T32; 3 K and other peer-reviewed awards. The annual direct NCI support in 2008 totaled $3.5 million. Our program has emphasized translational research to the clinic in diagnostics and novel therapeutics and from the clinic to the laboratory in the correlation of studies on tissues matched with clinical events. During the past five years, over 300 publications have appeared in peer-reviewed journals. Laboratory-based projects are focused on the detection of signaling pathways in individual cells; lymphomagenesis, with attention to the MYC oncogene and the immune response to hepatitis C; development of novel diagnostics, including new gene discovery and new monoclonal antibodies directed against these genes; and model systems for a new method of therapeutic vaccination. Our clinical studies have a focus on immunotherapy and novel combined modality treatments and concepts from our group have moved into influential Phase III clinical trials in the Eastern Cooperative Oncology Group (ECOG).